Study Reveals Empathy-Focused Interventions Have the Same Impact as Prescription Medications for Diabetes Control
This research builds on Kahlon's previous work studying the broader benefits of empathetic phone calls. In 2021, Kahlon and her team published a study that found 10-minute Sunshine Connections improved mental health for elderly patients.
Share
During the six-month clinical trial, 260 patients of the Federally Qualified Health Center (FQHC) Lone Star Circle Care with uncontrolled diabetes were split randomly into two groups—one receiving standard care and the other receiving both standard care and consistent phone calls. Referred to as Sunshine Connections, these calls were made by empathetically talented nonmedical staff, creating opportunities for participants to share their experiences and day-to-day challenges in living with diabetes. This human-centered approach empowered trial participants to receive support at their own pace, fostering a strong personal connection and ongoing engagement with their callers beyond the clinical setting.
At the end of six months, the participants receiving Sunshine Connections saw:
Improved Blood Sugar Control: Patients saw an average HbA1c reduction of 0.7%, compared with no significant change in the control group.
Greater Impact for Patients with Mild or Greater Depressive Symptoms: Patients reporting mild depressive symptoms saw even larger reductions, with average HbA1c improvements of 1.1%.
High Satisfaction: Nearly all participants receiving Sunshine Connections rated them as very or extremely beneficial to their well-being.
'At a time when workforce shortages challenge health care delivery, this study underscores the profound clinical impact nonclinical staff can make,' said Jon Calvin, CEO of Lone Star Circle of Care. 'By leveraging trained laypeople, we're demonstrating that empathy, connection and intentional engagement can lead to measurable health improvements. In a world where medicine is increasingly fast-paced and technology-driven, this work reminds us that human connection remains at the heart of effective care. Empathy not only enhances patient engagement but empowers individuals to take meaningful steps toward better health outcomes.'
This research builds on the study's lead author, Maninder Kahlon, Ph.D., previous work studying the broader benefits of empathetic phone calls. In 2021, Kahlon and her team published a study that found 10-minute Sunshine Connections improved loneliness, depression, anxiety and overall mental health among mostly homebound, older adults. After just a four-week trial, participants reported feeling 20% less lonely on average. Symptoms of anxiety and depression also notably decreased, with more than a 30% decrease on the GAD-7 scale and 24% decrease on the PHQ-8 scale, respectively. Beheld is also working on a study examining the impact of Sunshine Connections on maternal health outcomes for Medicaid populations—this data is expected to be available by the end of summer 2025.
'Care relationships have deteriorated because healthcare rewards high-cost care over long-term human connection—and technology often deepens that gap. Approaches that lack connection lead to worse health outcomes, and at this point, the traditional healthcare system is too under-resourced to solve it. Beheld is changing that,' said Maninder 'Mini' Kahlon, Ph.D., lead author of the study, co-founder and CEO of Beheld, and associate professor in the Department of Population Health at Dell Med. 'Our study found that engaging nonmedical talented individuals to provide empathetic support has a meaningful impact on health conditions like diabetes; the impact is the clinical equivalent to improvements you would see from prescription medications. This approach holds massive potential for health plans looking to address other conditions in Medicaid and Medicare Advantage member populations.'
To learn more about Beheld, visit www.beheldhealth.com
About Beheld
Beheld delivers clinically relevant health improvements for members through the power of consistent, science-backed human connection. Co-founded by Dr. Maninder Kahlon, founding Vice Dean of Dell Medical School at UT Austin, Beheld aims to redefine traditional healthcare delivery using technology as an enabler for deeper understanding and trust. Partnering with health plans to tackle their biggest challenges, Beheld leverages its empathetically talented workforce and innovative technology to source unique insights into member populations to improve outcomes, quality metrics, and cost savings. To learn more, visit www.beheldhealth.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
24 minutes ago
- Business Wire
Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 8:00 a.m. ET to discuss its financial results and business updates for the second quarter of 2025. Investors and the general public are invited to listen to the live webcast and may register on the Investor Relations section of the Nuvation Bio website. To access the live conference call, participants can dial +1 833-470-1428 (U.S. toll-free) and enter access code 926066. An archived recording will be available on Nuvation Bio's website for 90 days following the event. About Nuvation Bio Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients' lives. Our diverse pipeline includes taletrectinib (IBTROZI™), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; NUV-1511, an innovative drug-drug conjugate (DDC) designed for targeted cancer treatment; and NUV-868, a BD2-selective BET inhibitor. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, visit or follow the company on LinkedIn and X (@nuvationbioinc).
Business Wire
24 minutes ago
- Business Wire
Healthpeak Properties Reports Second Quarter 2025 Results
DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: DOC), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the quarter ended June 30, 2025. SECOND QUARTER 2025 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS Net income of $0.05 per share, Nareit FFO of $0.43 per share, FFO as Adjusted of $0.46 per share, AFFO of $0.44 per share, and Total Merger-Combined Same-Store Cash (Adjusted) NOI growth of 3.5% On July 7, 2025, declared a monthly common stock cash dividend of $0.10167 per share for each of July, August, and September, of 2025 representing cash dividends totaling $0.305 per share for the third quarter, and an annualized dividend amount of $1.22 per share Second quarter new and renewal lease executions totaled 1.5 million square feet: Outpatient medical new and renewal lease executions totaled 1 million square feet, with 85% retention and +6% cash releasing spreads on renewals Subsequent to the second quarter and through July 24, 2025, executed 419,000 square feet of Outpatient medical leases with signed letters of intent on an additional 682,000 square feet Lab new and renewal lease executions totaled 503,000 square feet, with 87% retention and +6% cash releasing spreads on renewals Subsequent to the second quarter and through July 24, 2025, executed 55,000 square feet of Lab leases with signed letters of intent on an additional 253,000 square feet During the second quarter, entered into two new development agreements with a combined projected cost of $148 million to support Northside Hospital's continued outpatient expansion in the Atlanta market Sold one outpatient medical land parcel in June 2025 and two outpatient medical buildings in July 2025 for combined proceeds of approximately $35 million Balance Sheet Net Debt to Adjusted EBITDAre was 5.2x for the quarter ended June 30, 2025 As of July 24, 2025, Healthpeak had approximately $2.3 billion in available liquidity through a combination of unrestricted cash and availability under its revolving credit facility Launched a redesigned corporate website at to elevate visibility into Healthpeak's competitive advantage and core values Earned 2025 BOMA Mid Atlantic region TOBY Awards for 833 Chestnut Street (medical category) and Cambridge Discovery Park (life science category); TOBY (The Outstanding Building of the Year) Awards are among the most prestigious recognitions in commercial real estate, honoring commercial building management and operations excellence Recent corporate impact and sustainability achievements include: Published a standalone 2024 Environmental Data Report, marking our 14 th consecutive year of environmental performance transparency and reporting Awarded the Green Lease Leader Platinum designation by the Institute for Market Transformation and the Department of Energy Better Buildings Alliance Earned LEED Gold certifications for sustainable building design and construction at Callan Ridge in Torrey Pines, California, and 460 Forbes on the Vantage campus in South San Francisco, California, bringing Healthpeak's total LEED-certified square footage to 6.7 million as of June 30, 2025 Named a constituent of the FTSE4Good Index Series for the 14 th consecutive year To learn more about Healthpeak's commitment to responsible business and view our most recent Corporate Impact Report, please visit YEAR TO DATE COMPARISON Nareit FFO, FFO as Adjusted, AFFO, Total Merger-Combined Same-Store Cash (Adjusted) NOI, and Net Debt to Adjusted EBITDAre are supplemental non-GAAP financial measures that we believe are useful in evaluating the operating performance and financial position of real estate investment trusts (see the "Funds From Operations" and "Adjusted Funds From Operations" sections of this release for additional information). See "June 30, 2025 Discussion and Reconciliation of Non-GAAP Financial Measures" for definitions, discussions of their uses and inherent limitations, and reconciliations to the most directly comparable financial measures calculated and presented in accordance with GAAP in the Investor Relations section of our website at The table below outlines the year-over-year three-month and year-to-date total Merger-Combined SS Cash (Adjusted) NOI growth. DIVIDEND On July 7, 2025, Healthpeak's Board of Directors declared a monthly common stock cash dividend of $0.10167 per share for each of July, August, and September, of 2025 representing cash dividends totaling $0.305 per share for the third quarter, and an annualized dividend amount of $1.22 per share. The dividend is payable on the payment dates set forth in the table below to stockholders of record as of the close of business on the corresponding record date. Record Date Payment Date Amount July 18, 2025 July 31, 2025 $0.10167 per common share August 18, 2025 August 29, 2025 $0.10167 per common share September 19, 2025 September 30, 2025 $0.10167 per common share Expand NORTHSIDE OUTPATIENT MEDICAL DEVELOPMENTS During the second quarter of 2025, Healthpeak entered into two new outpatient development agreements in high-growth submarkets of Atlanta totaling $148 million to support the expansion of our longstanding partner, Northside Hospital. Affiliates of Northside have pre-leased 78% of each building for a range of clinical services, reflecting the system's continued investment in outpatient capacity across two premier campuses. Physician tenants will have the ability to co-invest in the buildings. Upon stabilization, Healthpeak expects to achieve cash yields in the mid-7% range. Northside Forsyth: $82 million, 118,000 square foot Class A outpatient medical building and accompanying parking deck located on the campus of Northside Hospital Forsyth, a 389-bed acute care hospital located in Cumming, Georgia, a northeastern suburb of Atlanta. Northside Cherokee: $66 million, 148,000 square foot Class A outpatient medical building located on the campus of Northside Hospital Cherokee, a 332-bed acute care hospital in Canton, Georgia, a northern suburb of Atlanta. SHARE REPURCHASE ACTIVITY As previously disclosed, in April 2025, Healthpeak repurchased 3.9 million shares at a weighted average share price of $18.22, totaling $72 million. As of July 24, 2025, approximately $406 million remained available for share repurchases under the program. BALANCE SHEET In June 2025, Healthpeak repaid $452 million 4.0% senior notes at maturity. As of July 24, 2025, Healthpeak had approximately $2.3 billion in available liquidity through a combination of unrestricted cash and its revolving credit facility. 2025 GUIDANCE We are reaffirming the following guidance ranges for full year 2025: Diluted FFO as Adjusted per share of $1.81 – $1.87 Total Merger-Combined Same-Store Cash (Adjusted) NOI growth of 3.0% – 4.0% We are updating the following guidance ranges for full year 2025: Diluted earnings per common share from $0.30 – $0.36 to $0.25 – $0.31 Diluted Nareit FFO per share from $1.81 – $1.87 to $1.78 – $1.84 These estimates are based on our current view of existing market conditions, transaction timing, and other assumptions for the year ending December 31, 2025. For additional details and assumptions, please see page 12 in our corresponding Supplemental Report and the Discussion and Reconciliation of Non-GAAP Financial Measures, both of which are available in the Investor Relations section of our website at CONFERENCE CALL INFORMATION Healthpeak has scheduled a conference call and webcast for Friday, July 25, 2025, at 8:00 a.m. Mountain Time. The conference call can be accessed in the following ways: An archive of the webcast will be available on Healthpeak's website through July 24, 2026, and a telephonic replay can be accessed through August 1, 2025, by dialing (800) 770-2030 and entering conference ID number 95156. ABOUT HEALTHPEAK Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT) and S&P 500 company. Healthpeak owns, operates, and develops high-quality real estate focused on healthcare discovery and delivery. FORWARD-LOOKING STATEMENTS Statements contained in this release that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements regarding our and our officers' intent, belief or expectation as identified by the use of words such as "may," "will," "project," "expect," "believe," "intend," "anticipate," "seek," "target," "forecast," "plan," "potential," "estimate," "could," "would," "should" and other comparable and derivative terms or the negatives thereof. Examples of forward-looking statements include, among other things: (i) statements regarding timing, outcomes and other details relating to current, pending or contemplated acquisitions, dispositions, developments, redevelopments, joint venture transactions, leasing activity and commitments, financing activities, or other transactions discussed in this release; (ii) the payment of a quarterly cash dividend; and (iii) the information presented under the heading "2025 Guidance Information." Pending acquisitions, dispositions, joint venture transactions, leasing activity, and financing activity, including those subject to binding agreements, remain subject to closing conditions and may not be completed within the anticipated timeframes or at all. Forward-looking statements reflect our current expectations and views about future events and are subject to risks and uncertainties that could significantly affect our future financial condition and results of operations. While forward-looking statements reflect our good faith belief and assumptions we believe to be reasonable based upon current information, we can give no assurance that our expectations or forecasts will be attained. Further, we cannot guarantee the accuracy of any such forward-looking statement contained in this release, and such forward-looking statements are subject to known and unknown risks and uncertainties that are difficult to predict. These risks and uncertainties include, but are not limited to: macroeconomic trends that may increase construction, labor and other operating costs; changes within the life science industry; significant regulation, funding requirements, and uncertainty faced by our lab tenants; factors adversely affecting our tenants', operators', or borrowers' ability to meet their financial and other contractual obligations to us; the insolvency or bankruptcy of one or more of our major tenants, operators, or borrowers; our concentration of real estate investments in the healthcare property sector, which makes us more vulnerable to a downturn in that specific sector than if we invested across multiple sectors; the illiquidity of real estate investments; our ability to identify and secure new or replacement tenants and operators; our property development, redevelopment, and tenant improvement risks, which can render a project less profitable or unprofitable and delay or prevent its undertaking or completion; the ability of the hospitals on whose campuses our outpatient medical buildings are located and their affiliated healthcare systems to remain competitive or financially viable; our ability to develop, maintain, or expand hospital and health system client relationships; operational risks associated with our senior housing properties managed by third parties, including our properties operated through structures permitted by the Housing and Economic Recovery Act of 2008, which includes most of the provisions previously proposed in the REIT Investment Diversification and Empowerment Act of 2007 (commonly referred to as 'RIDEA'); economic conditions, natural disasters, weather, and other conditions that negatively affect geographic areas where we have concentrated investments; uninsured or underinsured losses, which could result in a significant loss of capital invested in a property, lower than expected future revenues, and unanticipated expenses; our use of joint ventures may limit our returns on and our flexibility with jointly owned investments; our use of rent escalators or contingent rent provisions in our leases; competition for suitable healthcare properties to grow our investment portfolio; our ability to exercise rights on collateral securing our real estate-related loans; any requirement that we recognize reserves, allowances, credit losses, or impairment charges; investment of substantial resources and time in transactions that are not consummated; our ability to successfully integrate or operate acquisitions or internalize property management; the potential impact of unfavorable resolution of litigation or disputes and resulting rising liability and insurance costs; environmental compliance costs and liabilities associated with our real estate investments; our ability to satisfy environmental, social and governance and sustainability commitments and requirements, as well as stakeholder expectations; epidemics, pandemics, or other infectious diseases, including the coronavirus disease (Covid), and health and safety measures intended to reduce their spread; human capital risks, including the loss or limited availability of our key personnel; our reliance on information technology and any material failure, inadequacy, interruption, or security failure of that technology; the use of, or inability to use, artificial intelligence by us, our tenants, our vendors, and our investors; volatility, disruption, or uncertainty in the financial markets; increased borrowing costs, which could impact our ability to refinance existing debt, sell properties, and conduct investment activities; cash available for distribution to stockholders and our ability to make dividend distributions at expected levels; the availability of external capital on acceptable terms or at all; an increase in our level of indebtedness; covenants in our debt instruments, which may limit our operational flexibility, and breaches of these covenants; volatility in the market price and trading volume of our common stock; adverse changes in our credit ratings; the failure of our tenants, operators, and borrowers to comply with federal, state, and local laws and regulations, including resident health and safety requirements, as well as licensure, certification, and inspection requirements; required regulatory approvals to transfer our senior housing properties; compliance with the Americans with Disabilities Act and fire, safety, and other regulations; laws or regulations prohibiting eviction of our tenants; the requirements of, or changes to, governmental reimbursement programs such as Medicare or Medicaid; legislation to address federal government operations and administrative decisions affecting the Centers for Medicare and Medicaid Services; our participation in the Coronavirus, Aid, Relief and Economic Security Act Provider Relief Fund and other Covid-related stimulus and relief programs; changes in federal, state, or local laws or regulations that may limit our opportunities to participate in the ownership of, or investment in, healthcare real estate; our ability to successfully integrate our operations with Physicians Realty Trust and realize the anticipated synergies of our merger with Physicians Realty Trust and benefits of property management internalization; our ability to maintain our qualification as a real estate investment trust ('REIT'); our taxable REIT subsidiaries being subject to corporate level tax; tax imposed on any net income from 'prohibited transactions'; changes to U.S. federal income tax laws, and potential deferred and contingent tax liabilities from corporate acquisitions; calculating non-REIT tax earnings and profits distributions; tax protection agreements that may limit our ability to dispose of certain properties and may require us to maintain certain debt levels; ownership limits in our charter that restrict ownership in our stock; provisions of Maryland law and our charter that could prevent a transaction that may otherwise be in the interest of our stockholders; conflicts of interest between the interests of our stockholders and the interests of holders of Healthpeak OP, LLC ('Healthpeak OP') common units; provisions in the operating agreement of Healthpeak OP and other agreements that may delay or prevent unsolicited acquisitions and other transactions; our status as a holding company of Healthpeak OP; and other risks and uncertainties described from time to time in our Securities and Exchange Commission filings. Moreover, other risks and uncertainties of which we are not currently aware may also affect our forward-looking statements, and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements made in this communication are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by us on our website or otherwise. We do not undertake any obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made. Healthpeak Properties, Inc. Consolidated Statements of Operations In thousands, except per share data Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Revenues: Rental and related revenues $ 529,687 $ 546,781 $ 1,067,828 $ 1,008,814 Resident fees and services 148,855 140,891 297,782 279,667 Interest income and other 15,806 7,832 31,627 13,583 Total revenues 694,348 695,504 1,397,237 1,302,064 Costs and expenses: Interest expense 75,063 74,910 147,756 135,817 Depreciation and amortization 265,916 283,498 534,462 502,717 Operating 276,181 273,827 549,324 517,556 General and administrative 20,764 26,718 46,882 50,017 Transaction and merger-related costs 10,215 7,759 15,749 114,979 Impairments and loan loss reserves (recoveries), net 3,499 (553 ) (63 ) 10,905 Total costs and expenses 651,638 666,159 1,294,110 1,331,991 Other income (expense): Gain (loss) on sales of real estate, net 1,636 122,044 1,636 125,299 Other income (expense), net (4,692 ) 4,004 (10,818 ) 82,520 Total other income (expense), net (3,056 ) 126,048 (9,182 ) 207,819 Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures 39,654 155,393 93,945 177,892 Income tax benefit (expense) (2,382 ) (2,728 ) (4,462 ) (16,426 ) Equity income (loss) from unconsolidated joint ventures 1,747 51 (400 ) 2,427 Net income (loss) 39,019 152,716 89,083 163,893 Noncontrolling interests' share in earnings (7,346 ) (6,669 ) (14,582 ) (11,170 ) Net income (loss) attributable to Healthpeak Properties, Inc. 31,673 146,047 74,501 152,723 Participating securities' share in earnings (115 ) (214 ) (579 ) (414 ) Net income (loss) applicable to common shares $ 31,558 $ 145,833 $ 73,922 $ 152,309 Earnings (loss) per common share: Basic $ 0.05 $ 0.21 $ 0.11 $ 0.23 Diluted $ 0.05 $ 0.21 $ 0.11 $ 0.23 Weighted average shares outstanding: Basic 695,188 702,382 697,117 651,642 Diluted 695,194 703,268 697,146 652,113 Expand Healthpeak Properties, Inc. Funds From Operations In thousands, except per share data Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Net income (loss) applicable to common shares $ 31,558 $ 145,833 $ 73,922 $ 152,309 Real estate related depreciation and amortization 265,916 283,498 534,462 502,717 Healthpeak's share of real estate related depreciation and amortization from unconsolidated joint ventures 12,530 11,621 24,730 20,393 Noncontrolling interests' share of real estate related depreciation and amortization (4,426 ) (4,732 ) (8,879 ) (9,174 ) Loss (gain) on sales of depreciable real estate, net (1,636 ) (122,044 ) (1,636 ) (125,299 ) Loss (gain) upon change of control, net (1) — (198 ) — (77,978 ) Taxes associated with real estate dispositions (2) (335 ) 49 (335 ) 11,657 Nareit FFO applicable to common shares 303,607 314,027 622,264 474,625 Distributions on dilutive convertible units and other 4,560 4,583 9,183 5,281 Diluted Nareit FFO applicable to common shares $ 308,167 $ 318,610 $ 631,447 $ 479,906 Diluted Nareit FFO per common share $ 0.43 $ 0.44 $ 0.89 $ 0.72 Weighted average shares outstanding - Diluted Nareit FFO 709,839 717,797 711,828 661,999 Impact of adjustments to Nareit FFO: Transaction and merger-related items (3) $ 10,215 $ 3,369 $ 15,749 $ 106,198 Other impairments (recoveries) and other losses (gains), net (4) 3,499 (553 ) 179 11,300 Casualty-related charges (recoveries), net (5) 3,919 (1,204 ) 8,145 (1,204 ) Total adjustments 17,633 1,612 24,073 116,294 FFO as Adjusted applicable to common shares 321,240 315,639 646,337 590,919 Distributions on dilutive convertible units and other 4,545 4,581 9,161 6,960 Diluted FFO as Adjusted applicable to common shares $ 325,785 $ 320,220 $ 655,498 $ 597,879 Diluted FFO as Adjusted per common share $ 0.46 $ 0.45 $ 0.92 $ 0.90 Weighted average shares outstanding - Diluted FFO as Adjusted 709,839 717,797 711,828 664,325 Expand _______________________________________ (1) The six months ended June 30, 2024 includes a gain upon change of control related to the sale of a 65% interest in two lab buildings in San Diego, California. The gain upon change of control is included in other income (expense), net in the Consolidated Statements of Operations. (2) The six months ended June 30, 2024 includes non-cash income tax expense related to the sale of a 65% interest in two lab buildings in San Diego, California. (3) The three and six months ended June 30, 2025 and 2024 includes costs related to the merger, which are primarily comprised of advisory, legal, accounting, tax, information technology, post-combination severance and stock compensation expense, and other costs of combining operations with Physicians Realty Trust that were incurred during the period. The three and six months ended June 30, 2025 also includes $6 million of costs incurred related to investments we are no longer pursuing. For the three and six months ended June 30, 2024, these costs were partially offset by termination fee income of $4 million and $9 million, respectively, associated with Graphite Bio, Inc., which later merged with LENZ Therapeutics, Inc. in March 2024, for which the lease terms were modified to accelerate expiration of the lease to December 2024. This termination fee income is included in rental and related revenues on the Consolidated Statements of Operations, but is excluded from Portfolio Cash Real Estate Revenues and FFO as Adjusted. (4) The three and six months ended June 30, 2025 and 2024 include reserves and (recoveries) for expected loan losses recognized in impairments and loan loss reserves (recoveries), net in the Consolidated Statements of Operations. (5) Casualty-related charges (recoveries), net are recognized in other income (expense), net, equity income (loss) from unconsolidated joint ventures, and noncontrolling interests' share in earnings in the Consolidated Statements of Operations. Expand Healthpeak Properties, Inc. Adjusted Funds From Operations In thousands, except per share data Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 FFO as Adjusted applicable to common shares $ 321,240 $ 315,639 $ 646,337 $ 590,919 Stock-based compensation amortization expense 1,738 4,814 6,365 8,180 Amortization of deferred financing costs and debt discounts (premiums) 7,875 7,317 15,727 11,840 Straight-line rents (5,401 ) (10,453 ) (16,554 ) (22,545 ) AFFO capital expenditures (25,729 ) (35,718 ) (48,864 ) (53,235 ) CCRC entrance fees (1) 19,042 12,117 23,739 19,502 Deferred income taxes 2,597 1,021 5,168 1,745 Amortization of above (below) market lease intangibles, net (10,085 ) (8,086 ) (20,296 ) (15,437 ) Other AFFO adjustments (1,069 ) (2,169 ) 381 (3,667 ) AFFO applicable to common shares 310,208 284,482 612,003 537,302 Distributions on dilutive convertible units and other 4,560 4,582 9,182 6,799 Diluted AFFO applicable to common shares (1) $ 314,768 $ 289,064 $ 621,185 $ 544,101 Diluted AFFO per common share (1) $ 0.44 $ 0.40 $ 0.87 $ 0.82 Weighted average shares outstanding - Diluted AFFO 709,839 717,797 711,828 663,975 Expand _______________________________________ (1) During the first quarter of 2025, we changed our definition of AFFO to adjust for the non-refundable entrance fees collected in excess of the related amortization as we believe the cash collection of these fees is a more meaningful representation of the performance of CCRCs in the determination of AFFO. Utilizing the prior definition for the three months ended June 30, 2025 and 2024, diluted AFFO applicable to common shares was $295.7 million and $276.9 million, respectively, and diluted AFFO per common share was $0.42 and $0.39, respectively. Utilizing the prior definition for the six months ended June 30, 2025 and 2024, diluted AFFO applicable to common shares was $597.4 million and $524.6 million, respectively, and diluted AFFO per common share was $0.84 and $0.79, respectively. Expand
Business Wire
24 minutes ago
- Business Wire
Edwards Lifesciences Reports Second Quarter Results
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2025. 2025 Outlook Increasing Edwards sales growth guidance to 9-10% from 8-10% Increasing TAVR sales guidance to 6-7% from 5-7%; reiterating TMTT and Surgical sales guidance Increasing adjusted 1 EPS guidance to the high-end of $2.40 to $2.50 Expected clinical presentations: 7-year PARTNER 3 low-risk, ENCIRCLE, TRISCEND II sub-analysis 'We are pleased to report strong second quarter results that delivered double-digit sales growth. Based on our better-than-expected first half performance and the many catalysts across our portfolio, we are confident in our full-year outlook and are raising our sales and EPS guidance,' said Bernard Zovighian, CEO. 'Edwards is increasingly distinguished by our balanced portfolio of leading therapies across aortic, mitral and tricuspid which will position us for leadership for many years to come as we help even more patients around the world.' Transcatheter Aortic Valve Replacement (TAVR) In the second quarter, the company reported TAVR sales of $1.1 billion, which grew 8.9% versus the prior year or 7.8% on a constant currency basis. Constant currency growth was comparable in the United States and outside of the U.S. On a global basis, Edwards' competitive position and pricing remained stable. TAVR growth in the quarter was better than expected, as clinicians continue to adopt Edwards' best-in-class SAPIEN technology. In the U.S., the clinical conversations around the EARLY TAVR trial data are bringing a renewed focus to streamlining the management of patients with severe aortic stenosis (AS), enabling closer follow-up and more timely treatment of patients with aortic stenosis. Outside of the U.S., the company continues to focus on the value of its differentiated technology and increasing therapy adoption, especially in areas where many patients go without care. In Europe, the exit of a competitor resulted in a rebalancing of market share and a modest contribution to Edwards' sales. In Japan, TAVR sales grew in the mid-single digits, an improvement over last quarter and consistent with the company's total sales growth in the region. Transcatheter Mitral and Tricuspid Therapies (TMTT) Edwards' unique TMTT portfolio of repair and replacement therapies to treat mitral and tricuspid diseases drove another quarter of impressive growth, with a meaningful contribution to overall company performance. Second quarter sales were $134.5 million or $133 million adjusted, representing growth of 61.9% year-over-year or 57.1% adjusted. Adoption of the company's differentiated PASCAL technology remains strong in both new and existing centers around the world. Edwards continues to see growing interest in the therapy, reinforcing the significant unmet needs of these patients. The EVOQUE system commercial launch is progressing well in the U.S. and Europe, with excellent real-world outcomes for patients consistent with the successful TRISCEND II clinical trial results. Edwards continues to see great demand for the therapy and continues to develop important evidence to support expansion globally. The company is pleased with the addition of its latest TMTT technology, the pioneering SAPIEN M3 mitral valve replacement system, which received CE Mark approval in Q2. Clinician feedback, while early, has been positive. With PASCAL, EVOQUE and the recent CE Mark of SAPIEN M3, Edwards' vision for TMTT has developed into a growth portfolio of groundbreaking transcatheter repair and replacement technologies, meeting the complex needs of underserved patients with mitral and tricuspid diseases. Surgical In Surgical, second quarter sales of $267 million increased 7.7% over the prior year, or 6.8% on a constant currency basis. The company continues to see positive procedure growth globally for the many patients best treated with its premium RESILIA tissue portfolio including the INSPIRIS, MITRIS and KONECT technologies. The company's KONECT aortic valved conduit received CE Mark approval in Europe during the quarter and the Surgical team made continued progress advancing important innovations around the world. Additional Financial Results For the quarter, the gross profit margin was 77.5%, in-line with the company's expectations, compared to 79.9% in the same period last year. This year-over-year change was driven by additional manufacturing expenses related to the expansion of new therapies as well as foreign exchange. Selling, general and administrative (SG&A) expenses in the second quarter were $502 million, or 32.8% of sales compared to $448 million in the same period last year. The company expects increased SG&A spending in the second half of the year due to deferral of certain spending year-to-date as well as anticipated spending related to JenaValve. Research and development (R&D) expense was $276 million in the quarter or 18.0% of sales, compared to $272 million or 19.8% of sales in the same period last year. This increase in spending and decrease in R&D as a percentage of sales reflects Edwards' strategic prioritization of investments in its expanding structural heart portfolio. Operating profit margin in the second quarter of 26.8%, or 28.2% adjusted, benefitted from the company's better-than-expected sales performance and the deferral of certain spending to the second half of the year. Cash and cash equivalents were approximately $3 billion as of June 30, 2025. Total debt was approximately $600 million. Outlook Edwards is increasing its full-year total company sales growth guidance to 9% to 10% with sales of $5.9 billion to $6.1 billion. In addition, the company is increasing its underlying growth rate guidance for TAVR to 6% to 7%, driven by strong performance, and its sales guidance range for TAVR to $4.3 billion to $4.5 billion. Sales guidance for the company's TMTT and Surgical product groups remains unchanged. The company now expects full-year adjusted EPS to be at the high end of its original range of $2.40 to $2.50. For the third quarter, the company projects total sales to be between $1.46 and $1.54 billion and adjusted EPS of $0.54 to $0.60. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at and follow us on LinkedIn, Facebook, Instagram and YouTube. Conference Call and Webcast Information The company will be hosting a conference call today at 2:00 p.m. PT to discuss its second quarter results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the 'Investor Relations' section of the Edwards website at or This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements can sometimes be identified by the use of words such as 'may,' 'will,' 'should,' 'anticipate,' 'believe,' 'plan,' 'project,' 'estimate,' 'forecast,' 'potential,' 'predict,' "early clinician feedback," 'expect,' 'intend,' 'guidance,' 'outlook,' 'optimistic,' 'aspire,' 'confident' or other forms of these words or similar expressions and include, but are not limited to, statements made by Mr. Zovighian and statements regarding the third quarter and fiscal year 2025 financial guidance, our expected growth and accelerating growth due to, among other things, asymptomatic TAVR approval; global adoption of, and differentiated features of, our devices; progress of the EVOQUE commercial launch; feedback on SAPIEN M3; our ability to deliver significant value to patients, healthcare ecosystem and shareholders; expansion of evidence, approvals, clinical trial outcomes and impacts; patient outcomes; the highlights in the Guidance and Outlook section and the information in the Outlook section. No inferences or assumptions should be made from statements of past performance, efforts, or results which may not be indicative of future performance or results. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain, difficult to predict, and may be outside of the company's control. The company's forward-looking statements speak only as of the date on which they are made and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. If the company does update or correct one or more of these statements, investors and others should not conclude that the company will make additional updates or corrections. Edwards' guidance reflects the Company's current estimates of the impact from tariffs that are in effect or have been announced as of the time of this press release and assumes such tariffs remain in place for the remainder of 2025. Any modification to such tariffs, or any new tariffs, could have a material impact on the Company's future financial results and guidance. Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include risk and uncertainties associated with the risks detailed in the company's filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2024, and its other filings with the SEC. These filings, along with important safety information about our products, may be found at Edwards, Edwards Lifesciences, the stylized E logo, EARLY TAVR, ENCIRCLE, EVOQUE, INSPIRIS, KONECT, MITRIS, PARTNER, PARTNER II, PARTNER 3, PASCAL, RESILIA, SAPIEN, SAPIEN M3, SAPIEN 3, SAPIEN 3 Ultra, TRISCEND, and TRISCEND II are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners. (in millions, except per share data) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Net sales $ 1,532.2 $ 1,369.4 $ 2,944.9 $ 2,699.3 Cost of sales 344.4 275.5 646.0 562.4 Gross profit 1,187.8 1,093.9 2,298.9 2,136.9 Selling, general, and administrative expenses 502.0 447.5 967.7 875.9 Research and development expenses 276.2 271.8 530.8 528.5 Certain litigation expenses 15.5 8.1 26.4 17.0 Separation costs 4.2 — 8.4 — Other operating income (21.3 ) — (40.4 ) — Operating income, net 411.2 366.5 806.0 715.5 Interest income, net (37.4 ) (15.5 ) (73.9 ) (32.0 ) Loss on impairment 47.1 — 47.1 — Other non-operating expense (income), net 1.3 (2.0 ) (1.3 ) (7.7 ) Income from continuing operations before provision for income taxes 400.2 384.0 834.1 755.2 Provision for income taxes 64.3 20.0 134.6 66.3 Net income from continuing operations 335.9 364.0 $ 699.5 $ 688.9 (Loss) income from discontinued operations, net of tax (4.4 ) 1.0 (11.6 ) 27.1 Net income 331.5 365.0 687.9 716.0 Net loss attributable to noncontrolling interest (1.7 ) (1.3 ) (3.3 ) (2.2 ) Net income attributable to Edwards Lifesciences Corporation $ 333.2 $ 366.3 $ 691.2 $ 718.2 Earnings (loss) per share: Basic: Continuing operations $ 0.58 $ 0.61 $ 1.20 $ 1.15 Discontinued operations $ (0.01 ) $ — $ (0.02 ) $ 0.04 Basic earnings per share $ 0.57 $ 0.61 $ 1.18 $ 1.19 Diluted: Continuing operations $ 0.57 $ 0.61 $ 1.20 $ 1.15 Discontinued operations $ (0.01 ) $ — $ (0.02 ) $ 0.04 Diluted earnings per share $ 0.56 $ 0.61 $ 1.18 $ 1.19 Weighted-average common shares outstanding: Basic 587.0 602.1 586.9 601.8 Diluted 587.9 604.3 587.9 604.2 Operating statistics from continuing operations As a percentage of net sales: Gross profit 77.5 % 79.9 % 78.1 % 79.2 % Selling, general, and administrative expenses 32.8 % 32.7 % 32.9 % 32.4 % Research and development expenses 18.0 % 19.8 % 18.0 % 19.6 % Operating income 26.8 % 26.8 % 27.4 % 26.5 % Income before provision for income taxes 26.1 % 28.0 % 28.3 % 28.0 % Net income from continuing operations 21.9 % 26.6 % 23.8 % 25.5 % Effective tax rate 16.1 % 5.2 % 16.1 % 8.8 % Expand ____________________ Note: Numbers may not calculate due to rounding. Expand EDWARDS LIFESCIENCES CORPORATION Non-GAAP Financial Information To supplement the consolidated financial results prepared in accordance with Generally Accepted Accounting Principles ('GAAP'), the Company uses non-GAAP historical financial measures. Management makes adjustments to the GAAP measures for items (both charges and gains) that (a) do not reflect the core operational activities of the Company, (b) are commonly adjusted within the Company's industry to enhance comparability of the Company's financial results with those of its peer group, or (c) are inconsistent in amount or frequency between periods (albeit such items are monitored and controlled with equal diligence relative to core operations). The Company uses the terms "adjusted" and 'constant currency" when referring to non-GAAP sales from continuing operations and sales growth information, respectively, which excludes currency exchange rate fluctuations and newly acquired products. The Company uses the term 'adjusted' to also exclude certain litigation expenses, amortization of intangible assets, loss on impairment, and separation costs. Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results, and evaluating current performance. These non-GAAP financial measures are used in addition to, and in conjunction with, results presented in accordance with GAAP and reflect an additional way of viewing aspects of the Company's operations by investors that, when viewed with its GAAP results, provide a more complete understanding of factors and trends affecting the Company's business and facilitate comparability to historical periods. Non-GAAP financial measures are not prepared in accordance with GAAP; therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. A reconciliation of non-GAAP historical financial measures to the most comparable GAAP measure is provided in the tables below. Fluctuations in currency exchange rates impact the comparative results and sales growth rates of the Company's underlying business. Management believes that excluding the impact of currency exchange rate fluctuations from its sales growth provides investors a more useful comparison to historical financial results. The impact of the fluctuations has been detailed in the "Reconciliation of Sales by Product Group and Region." Guidance for sales and sales growth rates is provided on a "constant currency basis," and projections for diluted earnings per share, net income and growth, gross profit margin, and taxes are also provided on a non-GAAP basis, as adjusted, for the items identified above due to the inherent difficulty in forecasting such items without unreasonable efforts. The Company is not able to provide a reconciliation of the non-GAAP guidance to comparable GAAP measures due to the unknown effect, timing, and potential significance of special charges or gains, and management's inability to forecast charges associated with future transactions and initiatives. The items described below are adjustments to the GAAP financial results in the reconciliations that follow: Certain Litigation Expenses - The Company incurred certain litigation expenses of $10.9 million and $8.9 million in the first quarter of 2025 and 2024, respectively, and $15.5 million and $8.1 million for the second quarter of 2025 and 2024, respectively. Amortization of Intangible Assets - The Company recorded amortization expense related to developed technology and patents in the amount of $1.4 million and $0.5 million in the first quarter of 2025 and 2024, respectively, and $1.8 million and $1.2 million in the second quarter of 2025 and 2024, respectively. Separation Costs - The Company recorded expenses of $4.2 million in both the first and second quarter of 2025 related to consulting, legal, tax, and other professional advisory services related to the sale of Critical Care. Loss on Impairment - The Company recorded other-than-temporary loss on impairment of $47.1 million ($37.6 million net of tax) in the second quarter of 2025, related to the Company's determination to not exercise an option to acquire one of its cost method investments. Provision for Income Taxes - The income tax impacts of the expenses and gains discussed above are based upon the items' forecasted effect upon the Company's full year effective tax rate. Adjustments to forecasted items unrelated to the expenses and gains above, as well as impacts related to interim reporting, will have an effect on the income tax impact of these items in subsequent periods. Three Months Ended June 30, 2024 Net Sales Gross Profit Margin Operating Income, net Operating Profit Margin Net Income Diluted EPS Effective Tax Rate GAAP - Continuing Operations $ 1,369.4 79.9 % $ 366.5 26.8 % $ 364.0 $ 0.61 5.2 % Net loss attributable to noncontrolling interests — — — — 1.3 — — Total attributable to Edwards Lifesciences Corporation 1,369.4 79.9 % 366.5 26.8 % 365.3 0.61 5.2 % Non-GAAP adjustments: (A) (B) Certain litigation expenses — — 8.1 0.5 6.5 0.01 0.1 Amortization of intangible assets — 0.1 1.2 0.1 1.0 — — Prior period ongoing tax impacts — — — — 0.8 — — Adjusted $ 1,369.4 80.0 % $ 375.8 27.4 % $ 373.6 $ 0.62 5.3 % Expand Six Months Ended June 30, 2025 GAAP - Continuing Operations $ 2,944.9 78.1 % $ 806.0 27.4 % $ 699.5 $ 1.20 16.1 % Net loss attributable to noncontrolling interests — — — — 3.3 — — Total attributable to Edwards Lifesciences Corporation 2,944.9 78.1 % 806.0 27.4 % 702.8 1.20 16.1 % Non-GAAP adjustments: (A) (B) Certain litigation expenses — — 26.4 0.9 20.8 0.03 0.2 Amortization of intangible assets — 0.1 3.2 0.1 2.6 — — Separation costs — — 8.4 0.3 6.6 0.02 0.1 Loss on impairment — — — — 37.6 0.06 0.1 Adjusted $ 2,944.9 78.2 % $ 844.0 28.7 % $ 770.4 $ 1.31 16.5 % Expand Six Months Ended June 30, 2024 GAAP - Continuing Operations $ 2,699.3 79.2 % $ 715.5 26.5 % $ 688.9 $ 1.15 8.8 % Net loss attributable to noncontrolling interests — — — — 2.2 — — Total attributable to Edwards Lifesciences Corporation 2,699.3 79.2 % 715.5 26.5 % 691.1 1.15 8.8 % Non-GAAP adjustments: (A) (B) Certain litigation expenses — — 17.0 0.6 13.9 0.03 0.1 Amortization of intangible assets — — 1.7 0.1 1.4 — — Prior period ongoing tax impacts — — — 0.8 — — Adjusted $ 2,699.3 79.2 % $ 734.2 27.2 % $ 707.2 $ 1.18 8.9 % Expand ____________________ (A) See description of non-GAAP adjustments under "Non-GAAP Financial Information." (B) The tax effect on non-GAAP adjustments is calculated based upon the impact of the relevant tax jurisdictions' statutory tax rates on the Company's estimated annual effective tax rate, or discrete rate in the quarter, as applicable. The impact on the effective tax rate is reflected on each individual non-GAAP adjustment line item. Expand 2025 Adjusted 2024 Adjusted Sales by Product Group (QTD) - Continuing Operations 2Q 2025 2Q 2024 Change GAAP Growth Rate* Implantable Heart Failure Management 2Q 2025 Adjusted Sales FX Impact 2Q 2024 Adjusted Sales Constant Currency Growth Rate * Transcatheter Aortic Valve Replacement $ 1,130.9 $ 1,038.6 $ 92.3 8.9 % $ — $ 1,130.9 $ 11.3 $ 1,049.9 7.8 % Transcatheter Mitral and Tricuspid Therapies 134.5 83.0 51.5 61.9 % (1.5 ) 133.0 1.7 84.7 57.1 % Surgical Structural Heart 266.8 247.8 19.0 7.7 % — 266.8 2.4 250.2 6.8 % Total $ 1,532.2 $ 1,369.4 $ 162.8 11.9 % $ (1.5 ) $ 1,530.7 $ 15.4 $ 1,384.8 10.6 % Expand 2025 Adjusted 2024 Adjusted Sales by Product Group (YTD) - Continuing Operations YTD 2Q 2025 YTD 2Q 2024 Change GAAP Growth Rate* Implantable Heart Failure Management YTD 2Q 2025 Adjusted Sales FX Impact YTD 2Q 2024 Adjusted Sales Constant Currency Growth Rate * Transcatheter Aortic Valve Replacement $ 2,177.5 $ 2,046.5 $ 131.0 6.4 % $ — $ 2,177.5 $ (3.8 ) $ 2,042.7 6.6 % Transcatheter Mitral and Tricuspid Therapies 249.7 155.9 93.8 60.1 % (1.9 ) 247.8 (0.1 ) 155.8 59.1 % Surgical Structural Heart 517.7 496.9 20.8 4.2 % — 517.7 (2.2 ) 494.7 4.7 % Total $ 2,944.9 $ 2,699.3 $ 245.6 9.1 % $ (1.9 ) $ 2,943.0 $ (6.1 ) $ 2,693.2 9.3 % Expand 2025 Adjusted 2024 Adjusted Sales by Region (QTD) - Continuing Operations 2Q 2025 2Q 2024 Change GAAP Growth Rate* Implantable Heart Failure Management 2Q 2025 Adjusted Sales FX Impact 2Q 2024 Adjusted Sales Constant Currency Growth Rate * United States $ 889.7 $ 806.4 $ 83.3 10.3 % $ (1.5 ) $ 888.2 $ — $ 806.4 10.1 % Europe 378.2 332.2 46.0 13.8 % — 378.2 13.1 345.3 9.6 % Japan 95.3 86.5 8.8 10.2 % — 95.3 5.1 91.6 4.2 % Rest of World 169.0 144.3 24.7 17.1 % — 169.0 (2.8 ) 141.5 19.5 % Outside of the United States 642.5 563.0 79.5 14.1 % — 642.5 15.4 578.4 11.3 % Total $ 1,532.2 $ 1,369.4 $ 162.8 11.9 % $ (1.5 ) $ 1,530.7 $ 15.4 $ 1,384.8 10.6 % Expand ____________________ * Numbers may not calculate due to rounding. Expand
